| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/11/2001 | WO2001001940A1 Compositions comprising organosiloxane resins for delivering oral care substances |
| 01/11/2001 | WO2001001932A2 Oligosaccharide aldonic acids and their topical use |
| 01/11/2001 | WO2001001922A2 Use of substance p antagonists for the treatment of adenocarcinoma |
| 01/11/2001 | WO2001001749A2 FVIIa ANTAGONISTS |
| 01/11/2001 | WO2000062657A3 Improvement of t cell mediated immunity |
| 01/11/2001 | WO2000061793A3 Novel method for identifying antibacterial compounds |
| 01/11/2001 | WO2000061543A3 Esters of l-carnitine or alkanoyl l-carnitines |
| 01/11/2001 | WO2000061167A3 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS |
| 01/11/2001 | WO2000061068A3 Anthelmintic compositions |
| 01/11/2001 | WO2000059515A3 Immunomodulating polymers |
| 01/11/2001 | WO2000059485A3 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor |
| 01/11/2001 | WO2000053748A3 Casb618 polynucleotides and polypeptides and their use |
| 01/11/2001 | WO2000053738A3 Methods and compositions for regulating memory consolidation |
| 01/11/2001 | WO2000053596A3 Imidazole compounds as histamine h3 ligands |
| 01/11/2001 | WO2000051546A3 Bupropion metabolites and methods of their synthesis and use |
| 01/11/2001 | WO2000048581A3 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 01/11/2001 | WO2000039278A8 Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| 01/11/2001 | WO2000037679A3 Method for determining the susceptibility to developing sepsis and therapeutics for the treatment of sepsis |
| 01/11/2001 | DE19929887A1 cDNA-Sequenzen von zwei Interakoren FANCIP2 und FANCIP3 des Fanconi-Anämie-Proteins der Komplementationsgruppe A cDNA sequences of two Interakoren FANCIP2 and FANCIP3 of the Fanconi anemia complementation group A-protein of the |
| 01/11/2001 | DE19916108C1 Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung With sugar residues substituted 1,4-benzothiazepine-1,1-dioxide derivatives, processes for their preparation and their use |
| 01/11/2001 | CA2643231A1 Norepinephrine reuptake inhibitors and methods of using the same |
| 01/11/2001 | CA2380875A1 Cell death related drug targets in yeast and fungi |
| 01/11/2001 | CA2378606A1 Agent for occluding blood vessels |
| 01/11/2001 | CA2378467A1 Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| 01/11/2001 | CA2378116A1 Human immune response molecules |
| 01/11/2001 | CA2377931A1 Novel mammalian calcium channels and related probes, cell lines and methods |
| 01/11/2001 | CA2377784A1 Novel genes and their use in the modulation of obesity, diabetes and energy imbalance |
| 01/11/2001 | CA2377734A1 Heparin compositions that inhibit clot associated coagulation factors |
| 01/11/2001 | CA2377684A1 Screening method |
| 01/11/2001 | CA2377382A1 Prevention and treatment of amyloid-associated disorders |
| 01/11/2001 | CA2375751A1 Use of cortisol antagonists in the treatment for heat failure |
| 01/11/2001 | CA2375157A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | CA2374358A1 Methods and compositions for regulating gut motility and food intake |
| 01/11/2001 | CA2373979A1 Pre-formed gel sheet |
| 01/11/2001 | CA2373960A1 Use of substance p antagonists for the treatment of adenocarcinoma |
| 01/11/2001 | CA2373940A1 Medicinal compositions for treating colorectal cancer |
| 01/11/2001 | CA2373885A1 Therapeutic agent for diseases caused by pth or pthrp |
| 01/11/2001 | CA2373884A1 Method for enhancing an immune response |
| 01/11/2001 | CA2373883A1 Method of reducing neuronal injury or apoptosis |
| 01/11/2001 | CA2373881A1 Use of an angiotensin ii type 1 receptor antagonist in the manufacture of a medicament for the treatment of cardiovascular complications |
| 01/11/2001 | CA2373879A1 Antiviral therapy |
| 01/11/2001 | CA2373735A1 Fviia antagonists |
| 01/11/2001 | CA2372742A1 Double transgenic animals as models for neurodegenerative disease |
| 01/10/2001 | EP1066830A2 Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/10/2001 | EP1066828A1 Medicaments |
| 01/10/2001 | EP1066761A2 Compositions containing fat-soluble substances in a carbohydrate matrix |
| 01/10/2001 | EP1066402A1 Methods of screening agents for activity using teleosts |
| 01/10/2001 | EP1066377A1 Methods for prevention and treatment of cancer |
| 01/10/2001 | EP1066323A1 Treatment and prevention of vascular disease |
| 01/10/2001 | EP1066319A1 Production methods and uses of a retrovirus |
| 01/10/2001 | EP1066311A1 Compositions and methods for the identification of lung tumor cells |
| 01/10/2001 | EP1066310A1 Neokine protein and nucleic acid molecules and uses therefor |
| 01/10/2001 | EP1066285A1 Antagonists of gonadotropin releasing hormone |
| 01/10/2001 | EP1066060A2 Mesenchymal stem cells as immunosuppressants |
| 01/10/2001 | EP1066048A1 A pharmaceutical preparation comprising an angiotensin ii type 2 receptor agonist, and use thereof |
| 01/10/2001 | EP1066043A2 Materials and methods relating to the treatment of conditions involving mast cells, basophils and eosinophils |
| 01/10/2001 | EP1066041A1 THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY |
| 01/10/2001 | EP1066038A2 Use of cabergoline in the treatment of restless legs syndrome |
| 01/10/2001 | EP1066036A1 Agents with serotonin-related activity for the treatment for sleep apnea |
| 01/10/2001 | EP1066035A2 Substituted aromatic compounds for treatment of antibiotic resistant infections |
| 01/10/2001 | EP1066034A1 Oxy-vanadium (iv) complexes having spermicidal activity |
| 01/10/2001 | EP1065931A1 Compositions containing a combination of a creatine compound and a second agent |
| 01/10/2001 | EP0863770A4 Contrast medium and its use |
| 01/10/2001 | CN1279689A Vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/10/2001 | CN1279617A Combination of an aldose reductase inhibitor and a glycogen phosphorglase inhibitor |
| 01/10/2001 | CN1279616A Synergistic composition and methods for treating neoplanstic or cancerous growths and for restoring or boosting hematopoiesis |
| 01/10/2001 | CN1279615A Combination of hypertensin converting enzyme inhibitor with a diuretic for treating microcirculation disorders |
| 01/10/2001 | CN1279606A Use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function |
| 01/10/2001 | CN1279605A Inihibition of lipoprotein oxidation |
| 01/10/2001 | CN1279112A Composition with carbohydrate matrix containing liposoluble substance |
| 01/10/2001 | CN1279068A Aqueous solution for parenteral absorption |
| 01/09/2001 | US6173202 Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
| 01/09/2001 | US6172114 Creatine supplement |
| 01/09/2001 | US6172107 Mycophenolate salt disintegrates selectively in intestines |
| 01/09/2001 | US6172105 3-n,n-dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1-benzopyran-5 -carboxamide hydrogen tartrate synergistic mixture; anxiolytic agents, antidepressents; obsessive compulsive and psychological disorders |
| 01/09/2001 | US6172096 Administering 4-pyrazolylbenzenesulfonamide derivatives to treat autoimmune diseases |
| 01/09/2001 | US6172090 Side effect reduction by administering an insulin sensitivity enhancer such as pioglitazone hydrochloride with a biguanide such as metformin |
| 01/09/2001 | US6172089 Pharmaceutical composition |
| 01/09/2001 | US6172088 Administering gonadotropin releasing hormone inhibitor |
| 01/09/2001 | US6172086 Methods and compositions for stimulating neurite growth |
| 01/09/2001 | US6172080 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/09/2001 | US6172071 Anticholesterol agent |
| 01/09/2001 | US6172068 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 01/09/2001 | US6172061 Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative |
| 01/09/2001 | US6172060 Therapy for sexual disorders |
| 01/09/2001 | US6172055 Therapy, prevention a neurodegenerative diseases |
| 01/09/2001 | US6172054 Angiostatic agent |
| 01/09/2001 | US6172049 Supplying macromolecules to cells |
| 01/09/2001 | US6171838 ratB |
| 01/09/2001 | US6171835 ribH |
| 01/09/2001 | US6171790 Human protease associated proteins |
| 01/09/2001 | US6171788 Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| 01/09/2001 | US6171787 Detecting polynucleotide of tumor necrosis factor-gamma in sample by contacting with polynucleotide of defined nucleotide sequence and determining binding/hybridization; diagnosis of inflammation and related disorders |
| 01/09/2001 | US6171786 Contacting cell with phosphoinositol-dependent phospholipase c inhibitor along with cytotoxic drug |
| 01/09/2001 | US6171620 Method of enhancing the efficacy of anti-tumor agents |
| 01/06/2001 | CA2313339A1 Compositions containing fat-soluble substances in a carbohydrate matrix |
| 01/04/2001 | WO2001001131A1 Screening methods for compounds that affect melanogenesis |
| 01/04/2001 | WO2001001130A1 METHODS AND COMPOSITIONS RELATING TO PANCREATIC ISLET AND β-CELL DYSFUNCTION |
| 01/04/2001 | WO2001000874A2 Cancer associated antigens and uses therefor |
| 01/04/2001 | WO2001000864A2 Nucleic acid binding of multi-zinc finger transcription factors |